Systemic Lupus Erythematosus Pipeline Market Analysis Report 2022: Comprehensive Insights About 60+ Companies and 60+ Pipeline Drugs -

·5 min read

DUBLIN, May 25, 2022--(BUSINESS WIRE)--The "Systemic Lupus Erythematosus - Pipeline Insight, 2022" clinical trials has been added to's offering.

This "Systemic Lupus Erythematosus- Pipeline Insight, 2022" report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Systemic Lupus Erythematosus pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

"Systemic Lupus Erythematosus- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Systemic Lupus Erythematosus pipeline landscape is provided which includes the disease overview and Systemic Lupus Erythematosus treatment guidelines.

The assessment part of the report embraces, in depth Systemic Lupus Erythematosus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Systemic Lupus Erythematosus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

The companies and academics are working to assess challenges and seek opportunities that could influence Systemic Lupus Erythematosus R&D. The therapies under development are focused on novel approaches to treat/improve Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus Emerging Drugs Chapters

This segment of the Systemic Lupus Erythematosus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Systemic Lupus Erythematosus Emerging Drugs

Obinutuzumab: Roche

Obinutuzumab (Gazyva/Gazyvaro) is an engineered monoclonal antibody designed to attach to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells. Gazyva/Gazyvaro is designed to attack and destroy targeted B-cells both directly and together with the body's immune system. Gazyva is marketed as Gazyvaro in the EU and Switzerland. The drug is currently in Phase III stage of development to treat Systemic lupus erythematosus.

Ianalumab: Novartis

Ianalumab (VAY736) is an anti-B-cell activating factor (BAFF) receptor fully human monoclonal antibody, engineered for direct ADCC-mediated B-cell depletion. The drug is currently in Phase II stage of clinical trial evaluation to treat SLE. Ianalumab is also being studied in other Novartis-led trials in chronic lymphocytic leukemia, rheumatoid arthritis and Idiopathic pulmonary fibrosis among other indications.

LABP-104: Landos Biopharma Inc.

LABP-104 is an oral, systemically distributed, small-molecule therapeutic candidate which activates LANCL2, a surface membrane-associated receptor that is responsible for modulating key cellular and molecular changes tied to autoimmune diseases. LABP-104 is currently in clinical development for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). To date, treatment with LABP-104 has reduced the production of interferon alpha in human PBMCs from SLE patients and provided protection from clinical disease and tissue pathology in mouse models of lupus. Landos has initiated a Phase 1 trial of LABP-104 in healthy volunteers for the treatment of SLE and RA.

Ex-204: Exinda Therapeutics

Ex-204 (Bendamustine oral) is an antineoplastic" or "cytotoxic drug. As per the company pipeline the Bendamustine oral is in preclinical stage for Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus: Therapeutic Assessment

This segment of the report provides insights about the different Systemic Lupus Erythematosus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Systemic Lupus Erythematosus

There are approx. 60+ key companies which are developing the therapies for Systemic Lupus Erythematosus. The companies which have their Systemic Lupus Erythematosus drug candidates in the most advanced stage, i.e. phase III include, Roche.

Systemic Lupus Erythematosus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Systemic Lupus Erythematosus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Systemic Lupus Erythematosus drugs.

Key Questions Answered

  • How many companies are developing Systemic Lupus Erythematosus drugs?

  • How many Systemic Lupus Erythematosus drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Systemic Lupus Erythematosus?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Systemic Lupus Erythematosus therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Systemic Lupus Erythematosus and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Roche

  • ImmuPharma

  • UCB

  • Idorsia Pharmaceuticals

  • Biogen

  • Novartis

  • Zenas Biopharma

  • Horizon Therapeutics

  • Provention Bio

  • Janssen Research & Development

  • AbbVie

  • Medsenic

  • Sanofi

  • Amgen

  • Pfizer

  • Merck KGaA

  • Resolve Therapeutics


  • Eli Lilly and Company

  • Corbus Pharmaceuticals

  • Corestem

  • Bristol-Myers Squibb

  • Alpine Immune Sciences

  • Kezar Life Sciences

  • Neovacs

  • Kangpu Biopharmaceuticals

  • InnoCare

  • Eisai

  • Boston Pharmaceuticals

Key Products

  • Cenerimod

  • BIIB059

  • Ianalumab

  • Obexelimab (XmAb5871)

  • Daxdilimab (VIB7734)

  • PRV-3279

  • Nipocalimab

  • ABBV 599

  • NKTR-358 (LY3471851)

  • Arscimed

  • SAR441344

  • Rozibafusp alfa

  • Efavaleukin alfa

  • PF-06700841

  • Enpatoran

  • RSLV-132

  • Aldesleukin

  • LY 3361237

  • Lenabasum

  • CS20AT04

  • Daratumumab

  • Iberdomide

For more information about this clinical trials report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting